Market Signal Briefing

SAN FRANCISCO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that it will release its fourth quarter and full year 2025 results on Thursday, March 5, 2026, after market close, and host a conference call to review the results at 4:30 pm ET the same day.

Conference Call Details

A live audio webcast of the call will be available online at https://investors.omadahealth.com. A replay will be available shortly after the conclusion of the call at the same link and will remain accessible for approximately 12 months.

Those participating via conference call can pre-register using the following link:

https://register-conf.media-server.com/register/BI58c6d7a71730445093f7ea7c02d33e97

About Omada Health

Omada Health (Nasdaq: OMDA) is on a mission to fix what’s broken in chronic care. Today's healthcare system poorly serves chronic conditions that require ongoing support between doctor visits, like obesity, diabetes, hypertension, and musculoskeletal disorders. Omada’s virtual-first model combines human-led care teams, connected devices, and AI-enabled technology to deliver personalized care at scale, including support for GLP-1 therapy. Omada has served more than one million members since launch across 2,000+ employers, health plans, and health systems. Learn more at omadahealth.com.

Contacts

Allan Kells
[email protected] 

Rose Ramseth
[email protected]

Virtual fireside chat scheduled for Thursday, February 12, 2026, from 1:30 PM to 1:55 PM ET

Access the webcast here

Carlsbad, CA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President and Chief Medical Officer, will participate in a virtual fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium on Thursday, February 12, 2026, from 1:30 PM to 1:55 PM ET.

The symposium will host analyst-led fireside chats and discussions with public and private companies exploring emerging targets and therapeutic approaches in immunology. In addition to the fireside chat, management will be available to participate in one-on-one in-person meetings with qualified members of the investor community who are registered to attend the conference.

A live webcast of the presentation will be accessible on the Events page in the Investors section of the Company’s website at palisadebio.com. A replay will be available following the live event and will be archived for a limited time.

About PALI-2108

PALI-2108 is a once-daily, oral prodrug designed for targeted delivery of PDE4 inhibition to the terminal ileum and colon through local bacterial bioactivation. The prodrug is pharmacologically inactive until it reaches the lower intestine, where bacterial enzymes convert it into the active PDE4 inhibitor at sites of inflammation and fibrosis. This targeted activation strategy prevents absorption in the upper gut, enables sustained local exposure with controlled systemic distribution, and is engineered to reduce peak plasma levels, thereby improving the overall therapeutic index and reducing tolerability limitations such as diarrhea, nausea and headache that have constrained systemic PDE4 inhibitors.

About Palisade Bio

Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”) is a clinical-stage biopharmaceutical company advancing a next generation oral PDE4 inhibitor prodrugs designed to improve pharmacology, tolerability and convenience for patients with inflammatory and fibrotic diseases. Through its differentiated prodrug platform and precision pharmacology strategy, Palisade Bio is committed to transforming proven PDE4 biology into better, safer oral therapies for patients living with chronic inflammatory and fibrotic diseases.

The Company’s lead program, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug designed to be selectively bioactivated in the ileum and colon, initiating targeted PDE4 inhibition at sites of disease while enabling systemic distribution of the active drug. In a recently reported Phase 1b trial, PALI-2108 achieved a 100% clinical response in the UC cohort, with no serious adverse events, favorable tolerability and pharmacokinetics consistent with localized activation in the lower intestine, low systemic exposure, and controlled release within the GI tract.

Palisade Bio is now advancing towards a Phase 2 clinical study in UC designed to evaluate clinical remission, response and pharmacodynamic biomarkers over 12 weeks, with an extension phase assessing maintenance of remission. In addition, the Company is completing early studies in FSCD to further characterize PALI-2108’s safety, pharmacology and potential therapeutic benefit across inflammatory bowel disease indications. For more information, please go to www.palisadebio.com.

Forward Looking Statements

Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include but are not limited to: statements regarding the timing and results of clinical trials, the potential mechanisms of action and therapeutic benefits of PALI-2108, and plans for regulatory submissions. These forward-looking statements are based on the Company’s current expectations. Forward-looking statements involve risks and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the Company’s forward-looking statements include, among others, the timing of enrollment, commencement and completion of the Company’s clinical trials; the Company’s reliance on PALI-2108, and its early stage of clinical development; the risk that prior results, such as signals of safety, activity, dosing or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving the Company’s product candidates in clinical trials focused on the same or different indications; and other factors that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 24, 2025, and the Quarterly Reports on Form 10-Q or other SEC filings that are filed thereafter. Investors are cautioned not to put undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Investor Relations Contact

JTC Team, LLC
Jenene Thomas
908-824-0775
[email protected]

Kroger is a resilient, value 'Buy', amid market volatility, offering defensive growth and operational leverage. KR's e-commerce sales are a core growth driver, achieving a $14B annual run-rate and six quarters of double-digit growth, supported by third-party fulfillment partnerships. Management guides for 7% EPS growth in FY2026, driven by private-label strength, AI efficiencies, and accelerated store expansion.

The Cambria Tail Risk ETF offers downside protection for a stock portfolio via S&P 500 put options and U.S. Treasuries. TAIL outperforms inverse S&P 500 ETFs (SH, SDS) on risk-adjusted returns when used to hedge a core stock portfolio. The mid-term VIX futures ETF delivers superior risk-adjusted returns vs. TAIL but requires monitoring due to VIX futures complexity.

Credo Technology has dropped ~26%, despite no fundamental deterioration, presenting a compelling GARP opportunity ahead of earnings. CRDO's Q3 revenue is guided at $340M, with ~65% gross margin; consensus expects $342.33M revenue and $0.78 EPS, implying 212% YoY EPS growth. CRDO's expanding product suite, new hyperscaler customers, and leadership in high-speed connectivity underpin a bullish outlook and potential for stock doubling.

Key Takeaways Wall Street ended mixed last week as tech and software stocks sold off amid rising AI disruption fears.Anthropic's AI launch sparked panic selling in legal software and publishing stocks.Leveraged ETFs jumped as Lumentum, Enphase and Arm rallied, while IREN's drop boosted inverse gains. Wall Street offered a muted performance last week. The S&P 500 lost 0.1%, the Dow Jones added 2.5%, and the Nasdaq Composite retreated 1.8%. The key event of the week was the tech stock rout. Wall Street has been skeptical about software stocks in recent times, but a phase of outright panic hit last week. 

Traders dumped shares across the sector as fears mount that artificial intelligence (AI) could fundamentally disrupt software-as-a-service (SaaS) business models.The anxiety intensified on Feb. 3, 2026, after AI startup Anthropic unveiled a productivity tool aimed at in-house lawyers. The announcement triggered a sharp selloff in legal software and publishing stocks, per Bloomberg, as quoted on Yahoo Finance.

Meanwhile, six out of all Mag 7 members have reported their Q4 results, with just NVDA remaining. Alphabet and Amazon reported last week.Amazon missed EPS estimates, but the business is otherwise in great shape.

Amazon plans to spend $200 billion in capital expenditures in 2026, up from $132 billion in 2025 and $83 billion in 2024. While Amazon remains the cloud leader, the Alphabet report showed accelerating momentum at the search giant’s Google Cloud business (read: Amazon Drops on Mixed Q4 & Capex Outlook: Buy the Dip With ETFs?).

In a nutshell, combining the actual results for the six Magnificent 7 members that have reported already along with estimates for Nvidia, total Q4 earnings for the group are expected to be up 24.2% from the same period last year on 18.9% higher revenues, which would follow the group’s 28.3% earnings growth on 18.1% revenue growth in 2025 Q3, per Zacks Earnings Trends.

Against this backdrop, below we highlight the winning leveraged ETFs of last week.

Winning Leveraged ETFs in Focus Tradr 2X Long LITE Daily ETF (LITX - Free Report) – Up 79.5%

Lumentum Holdings Inc (LITE - Free Report) stock surged 36.3% last week on the earnings strength. Lumentum's Q1 2026 revenues rose 58% year over year to $533.8 million, topping estimates by 1.43%. Non-GAAP EPS of $1.10 beat the Zacks Consensus Estimate by 6.8%, driven by AI and cloud strength. The company offered an upbeat outlook, too.

Tradr 2X Long ENPH Daily ETF (ENPX - Free Report) – Up 67.7%

Enphase Energy (ENPH - Free Report) shares rose 35.8% last week. Enphase last weekreported fourth-quarter 2025 adjusted earnings of 71 cents per share, which topped the Zacks Consensus Estimate of 54 cents by 31.5%.Enphase Energy’s fourth-quarter revenues of $343.3 million beat the Zacks Consensus Estimate of $335 million by 2.6%.

Tradr 2X Short IREN Daily ETF (IREZ - Free Report) – Up 37.1%

IREN Ltd (IREN - Free Report) lost about 20.1% last week, lending a surge to the double-leveraged IREN ETF. Last week, IREN came with a Q2 FY26 loss of 44 cents per share as revenues slid 23.1% sequentially and missed estimates. Total revenues fell 23.1% sequentially to $184.7 million, missing the consensus estimate by 16.49%. Bitcoin revenues fell 28.2% quarter on quarter. However, AI cloud services revenues jumped 137% from the prior quarter.

T-Rex 2X Long ARM Daily Target ETF (ARM - Free Report) U) – Up 35.0%

Arm Holdings (ARM - Free Report) gained about 18% last week. The stock gained on a strong fiscal third-quarter 2026 earnings report released on Feb. 4, 2026. The stock gained as investors focused on strong growth in AI and data center segments.

February 09, 2026 09:02 ET  | Source: NexGold Mining Corp.

TORONTO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- NexGold Mining Corp. (TSXV: NEXG; OTCQX: NXGCF) (“NexGold” or the “Company”) announces that the Board of Directors of the Company has approved grants of 671,742 Restricted Share Units (RSUs) and 348,607 Deferred Share Units (DSUs) to officers and non-executive directors under its 2024 Omnibus Equity Incentive Plan, as amended, in line with TSX Venture Exchange policies. The RSUs and DSUs vest in three equal tranches starting one year from the grant date. Each unit converts to one common share of the Company upon settlement in accordance with the Plan. The grants aim to align leadership interests with shareholders, recognize contributions and support long-term retention and performance.

About NexGold Mining Corp.

NexGold is a gold-focused company with assets in Canada and Alaska. NexGold’s Goldboro Gold Project is located in Nova Scotia. The Goliath Gold Complex (which includes the Goliath, Goldlund and Miller deposits) is located in Northwestern Ontario. NexGold also owns several other projects throughout Canada, including the Weebigee-Sandy Lake Gold Project JV, and grassroots gold exploration property Gold Rock. In addition, NexGold holds a 100% interest in the high-grade Niblack copper-gold-zinc-silver VMS project, located adjacent to tidewater in southeast Alaska. NexGold is committed to inclusive, informed and meaningful dialogue with regional communities and Indigenous Nations throughout the life of all our projects and on all aspects, including creating sustainable economic opportunities, providing safe workplaces, enhancing of social value, and promoting community wellbeing.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

February 09, 2026 08:00 ET  | Source: ProQR Therapeutics N.V.

LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that Dinko Valerio, a co-founder of the Company, and Alison Lawton will rotate off the Board at the Company’s next Annual General Meeting (AGM) as their terms conclude. 

The planned changes to ProQR’s Board composition at its 2026 AGM reflect the Company’s development as it advances its clinical programs, as well as its ongoing commitment to strong corporate governance and long-term succession planning. An executive search firm has been engaged to assist ProQR in identifying candidates to be nominated to the Board to support long-term value creation for all its stakeholders.

“On behalf of the Board, I would like to sincerely thank Dinko for his leadership, which has played a central role in shaping ProQR’s vision and strategy, and Alison for her insight, dedication, and many valuable contributions to the Company during her tenure,” said James Shannon, MD, Chairperson of the Board of ProQR Therapeutics. “Their efforts have had a meaningful impact on ProQR, and we are deeply grateful for their expertise.”

“Dinko and Alison have brought meaningful perspective and presence to the Board,” said Daniel A. de Boer, Founder and Chief Executive Officer of ProQR. “I have greatly appreciated their insights and contributions, and I look forward to continuing to work closely with the Board as we execute our strategy and advance our clinical and pipeline programs.”

As part of its ongoing governance practices, the Board regularly reviews its composition to ensure it maintains an appropriate balance of skills, experience, and perspectives to support ProQR’s long-term strategic objectives. This process has resulted in the appointment of two new Board members in the last three years.

About Axiomer™

ProQR is pioneering a next-generation RNA base editing technology called Axiomer™, which could potentially yield a new class of medicines for diverse types of diseases. Axiomer™ “Editing Oligonucleotides”, or EONs, mediate single nucleotide changes to RNA in a highly specific and targeted way using molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer™ EONs are designed to recruit and direct endogenously expressed ADARs to change an Adenosine (A) to an Inosine (I) in the RNA – an Inosine is translated as a Guanosine (G) – correcting an RNA with a disease-causing mutation back to a normal (wild type) RNA, modulating protein expression, or altering a protein so that it will have a new function that helps prevent or treat disease.

About ProQR

ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation RNA technology called Axiomer™, which uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unmet need. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.

Learn more about ProQR at www.proqr.com.

Forward Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “continue,” "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Such forward-looking statements include, but are not limited to, statements regarding our business, technology and strategy, the anticipated timing and implementation of planned changes to the Board composition, expectations regarding corporate governance practices and long-term succession planning, and the continued advancement of our pipeline programs. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those expressed or implied by these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our most recent annual report filed on Form 20-F. These risks and uncertainties include, among others, the cost, timing and results of preclinical studies and clinical trials and other development activities by us and our collaborative partners whose operations and activities may be slowed or halted shortage and pressure on supply and logistics on the global market, economic sanctions and international tariffs; the likelihood of our preclinical and clinical programs being initiated and executed on timelines provided and reliance on our contract research organizations and predictability of timely enrollment of participants and patients to advance our clinical trials and maintain their own operations; our reliance on contract manufacturers to supply materials for research and development and the risk of supply interruption from a contract manufacturer; the potential for future data to alter initial and preliminary results of early-stage clinical trials; the unpredictability of the duration and results of the regulatory review of applications or clearances that are necessary to initiate and continue to advance and progress our clinical programs; the ability to secure, maintain and realize the intended benefits of collaborations with partners, including the collaboration with Lilly; the possible impairment of, inability to obtain, and costs to obtain intellectual property rights; possible safety or efficacy concerns that could emerge as new data are generated in research and development; general business, operational, financial and accounting risks, and risks related to litigation and disputes with third parties; and risks related to macroeconomic conditions and market volatility resulting from global economic developments, geopolitical events and conflicts, high inflation, changing interest rates, tariffs and potential for significant changes in U.S. policies and regulatory environment. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

ProQR Therapeutics N.V.

Investor and media contact:
Sarah Kiely
ProQR Therapeutics N.V.
T: +1 617 599 6228
[email protected]
or
Investor contact:
Peter Kelleher
LifeSci Advisors
T: +1 617 430 7579
[email protected]

February 09, 2026 08:00 ET  | Source: Voyager Therapeutics, Inc.

LEXINGTON, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company will participate in the following upcoming investor conferences:

Guggenheim Emerging Outlook: Biotech Summit 2026: Fireside chat at 1:00 p.m. ET on Wednesday, February 11, 2026, in New York, NY.Oppenheimer 36th Annual Healthcare Life Sciences Conference: Fireside chat at 3:20 p.m. ET on Thursday, February 26, 2026.TD Cowen 46th Annual Health Care Conference: Fireside chat at 1:10 p.m. ET on Monday, March 2, 2026, in Boston, MA.Leerink Global Healthcare Conference 2026: Fireside chat at 10:40 a.m. ET on Tuesday, March 10, 2026, in Miami, FL.Stifel 2026 CNS Days: Fireside chat on Wednesday, March 18, 2026. A webcast of the Oppenheimer fireside chat will be available and may be accessed from the Investors section of Voyager’s website at ir.voyagertherapeutics.com. A replay of the webcast will be archived on the company’s website for at least 30 days.

About Voyager Therapeutics

Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; and Neurocrine Biosciences, Inc. For more information, visit http://www.voyagertherapeutics.com.

Voyager Therapeutics® is a registered trademark, and TRACER™ and Voyager NeuroShuttle™ are trademarks, of Voyager Therapeutics, Inc.

Contacts

Trista Morrison, NACD.DC, [email protected]
Investors: Sarah McCabe, [email protected]
Media: Adam Silverstein, [email protected]

BOCA RATON, Fla., Feb. 09, 2026 (GLOBE NEWSWIRE) -- ADT Inc. (NYSE: ADT) today announced its inclusion into the S&P SmallCap 600® Index, effective prior to the opening of trading this morning, Feb. 9, 2026.

“ADT’s inclusion in the S&P SmallCap 600 represents an important milestone for our company and reflects the resilience of our recurring revenue model and the progress we’ve made strengthening our business and delivering consistent performance,” said ADT Chairman, President and CEO, Jim DeVries. “As we remain focused on serving our customers, generating strong cash flow, and executing our strategy, we believe this addition will enhance our visibility within the investment community and highlight the long-term value we are creating for our shareholders, employees, and communities.”

For more information on the S&P SmallCap 600® and S&P Dow Jones Indices, please visit www.spdji.com. 

Forward-Looking Statements

ADT has made statements in this press release that are forward-looking and therefore subject to risks and uncertainties. All statements, other than statements of historical fact, included in this press release are, or could be, “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) and are made in reliance on the safe harbor protections provided thereunder.

These forward-looking statements relate to, among other things, the anticipated impacts of ADT’s inclusion in the S&P SmallCap 600® Index, including any statements regarding potential enhanced visibility within the investment community, as well as the Company’s strategy, operational priorities, and future performance, including statements regarding cash flow and long-term value creation.

Without limiting the generality of the preceding sentences, any time we use words such as “ongoing,” “expects,” “intends,” “will,” “anticipates,” “believes,” “confident,” “possible,” “continue,” “seeks,” “could,” “may,” “should,” “estimates,” “forecasts,” “might,” “potential,” “outlook,” “goals,” “objectives,” “targets,” “planned,” “projects,” and, in each case, their negative or other various or comparable terminology, and similar expressions, we intend to clearly express that the information deals with possible future events and is forward-looking in nature. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking.

These forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. We caution that these statements are subject to risks and uncertainties, many of which are outside of the Company’s control and could cause future events or results to be materially different from those stated or implied in this press release. Factors that could cause such differences include those described in the Company’s most recently filed Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, including the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained in those reports, and in the Company’s other filings with the SEC.

Any forward-looking statement made in this press release speaks only as of the date on which it is made. ADT undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise unless required by law.

About ADT 

ADT is a leading provider of security, interactive, and smart home solutions serving residential and small business customers in the U.S. Through innovative offerings, unrivaled safety, and a premium customer experience delivered by the largest network of smart home security professionals in the U.S., ADT empowers people to protect and connect to what matters most, every second, every day. For more information, visit ADT.com.

February 09, 2026 08:00 ET  | Source: 4D Molecular Therapeutics, Inc.

Enrollment for 4FRONT-1, the first registrational trial for 4D-150 in wet AMD, was completed within an approximately 11-month period, ahead of initial projections 4FRONT-1 overenrolled and expected to exceed 500 patients randomized, reflecting strong interest from investigators and patients Topline data from 4FRONT-1 expected in H1 20274FRONT-2 global site activation momentum continues, with enrollment completion on track for H2 2026 and topline data expected in H2 2027 EMERYVILLE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced enrollment completion for 4FRONT-1, the first Phase 3 clinical trial evaluating 4D-150 in patients with wet age-related macular degeneration (wet AMD).

“The 4D-150 4FRONT-1 Phase 3 trial enrolled in 11 months in a treatment-naïve large market patient population. This is a landmark moment for 4DMT, for wet AMD patients and for our targeted and locally delivered genetic medicines,” said David Kirn, M.D., Co-founder, President, and Chief Executive Officer of 4DMT. “This high enrollment rate and over-enrollment in the front-line wet AMD setting reflects investigator and patient enthusiasm for 4D-150 as a potential backbone therapy. Remarkably, our team achieved this milestone in only four years after treating the first patient with 4D-150 in wet AMD. I want to extend my heartfelt congratulations to the entire 4DMT team for their tireless work, dedication, and execution in reaching this achievement. We look forward to continuing this momentum as we accelerate global enrollment in our second Phase 3 study, 4FRONT-2.”

“For far too long, wet AMD patients have faced the burden of relentless, lifelong repeated bolus injections and vision loss,” said Julie Clark, M.D., Chief Medical Officer of 4DMT. “Our vision is to fundamentally shift that paradigm, to bring forward a potential backbone therapy that meaningfully reduces treatment burden while sustaining vision outcomes. The rapid enrollment completion, driven by the enthusiasm for 4D-150 and data generated to date, energizes our entire organization as we work relentlessly toward completing global enrollment in 4FRONT-2 and prepare for topline data in H1 2027 from 4FRONT-1. I want to thank all our sites, study coordinators, and patients for their partnership and trust as we work toward our goal to drive a new standard of care for wet AMD.”

“As retina specialists, we routinely observe the challenges long-term intravitreal injection regimens pose for wet AMD patients and their association with suboptimal long-term vision outcomes in real-world practice,” said Arshad M. Khanani, M.D., M.A., FASRS, Director of Clinical Research at Sierra Eye Associates, Chair of the 4DMT Ophthalmology Advisory Board and a principal investigator in the 4FRONT-1 clinical trial. “Based on the long-term PRISM Phase 1/2 data, 4D-150 has the potential to significantly reduce treatment burden for patients with wet AMD, with a single in-office intravitreal injection providing sustained disease control. The rapid enrollment of 4FRONT-1 in treatment-naïve patients is particularly encouraging and reflects strong enthusiasm among physicians and patients for therapies that offer potentially safe, effective, and durable long-term disease control. This progress is also a testament to the strong execution and deep expertise of the 4DMT team in advancing Phase 3 clinical trials. I look forward to the continued advancement of the 4FRONT registrational program.”

4FRONT-1 is a Phase 3 multicenter, randomized, double-masked, aflibercept 2 mg (Q8W) comparator-controlled study of intravitreal 4D-150 in wet AMD. The primary endpoint is non-inferiority in the mean change from baseline in best corrected visual acuity (BCVA) at 52 weeks. The key secondary endpoint is treatment burden reduction comparing the number of aflibercept injections received in the 4D-150 arm versus the aflibercept comparator arm over 52 weeks. Patients in both arms will be eligible for supplemental aflibercept injections. 4FRONT-1 is evaluating treatment-naïve wet AMD patients at sites in North America. Topline primary endpoint data from 4FRONT-1 is expected in H1 2027. Our second Phase 3 for wet AMD, 4FRONT-2, is a global trial with an identical design to 4FRONT-1 except for enrolling both treatment-naïve and recently diagnosed treatment-experienced wet AMD patients. 4FRONT-2 is expected to complete enrollment in H2 2026 with topline primary endpoint data expected in H2 2027.

About 4D-150

4D-150 is a potential backbone therapy designed to provide multi-year, and potentially lifelong, sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) within the retina following a single, safe, intravitreal injection. 4D-150 utilizes our customized and evolved intravitreal AAV vector, R100, which was invented at 4DMT through our proprietary Therapeutic Vector Evolution platform. 4D-150 is being developed for wet AMD and diabetic macular edema (DME), which both affect millions of patients globally, with the goal of freeing patients from burdensome injections while preserving vision.

About Wet AMD

Wet AMD, or wet age-related macular degeneration, is a highly prevalent disease, with more than 4 million individuals expected to be affected in the next five years in certain major markets, including the U.S., the EU and Japan. The disease also has a high incidence, with 200,000 individuals estimated to be newly diagnosed every year in the U.S. alone. Wet AMD is a type of macular degeneration in which abnormal blood vessels grow into the macula (macular neovascularization or MNV), the central area of the retina. MNV causes swelling and edema of the retina, bleeding and scarring, leading to visual distortion and reduced visual acuity. The proliferation and leakage of abnormal blood vessels is stimulated by VEGF. This process distorts and, without treatment, can potentially destroy central vision and may progress to blindness.

About 4DMT  

4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients with retina diseases. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and the second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.  

All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied. 

Learn more at www.4DMT.com and follow us on LinkedIn. 

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the therapeutic potential and clinical benefits of, as well as the plans, announcements and related timing for the clinical development, regulatory interactions, and potential commercialization of our product candidates, including 4D-150. The words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “expect,” “estimate,” “seek,” “predict,” “future,” “project,” “potential,” “continue,” “target,” and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties, and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including: (i) risks that clinical trial results may not support regulatory approval or demonstrate sustained therapeutic benefit; (ii) risks that our product candidates may not demonstrate sufficient safety or efficacy; (iii) risks related to regulatory approval processes and evolving standards for gene therapies; (iv) risks that 4D Molecular Therapeutics may not receive necessary funding or may require additional capital for its operations and anticipated commercialization; (v) risks related to manufacturing complexity and supply chain for gene therapies; and (vi) risks of competition and rapidly evolving treatment landscape; as well as other risks and uncertainties that are described in greater detail in the section entitled "Risk Factors" in 4D Molecular Therapeutics’ most recent Quarterly Report on Form 10-Q filed on November 10, 2025, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statement represents 4D Molecular Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. 4D Molecular Therapeutics undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release, except as may be required by law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Contacts:

Media:
Jenn Gordon
dna Communications
[email protected]

Investors:
Julian Pei
Head of Investor Relations and Strategic Finance
[email protected]

VANCOUVER, British Columbia, Feb. 09, 2026 (GLOBE NEWSWIRE) -- NOVAGOLD RESOURCES INC. (“NOVAGOLD” or the “Company”) (NYSE American, TSX: NG) and Donlin Gold Holdings (DGH), 100% wholly-owned by Paulson Advisers LLC (“Paulson”) and its affiliates, are pleased to announce that Fluor Corporation (NYSE: FLR) (“Fluor”) was selected to lead the Bankable Feasibility Study (BFS) as the engineering firm for the Donlin Gold project in Alaska as it advances toward financing and development.

Donlin Gold is advancing the BFS using a disciplined, execution-focused approach informed by longstanding experience in delivering large, multi-disciplinary projects. The emphasis is on fully integrating scope, engineering, cost, and schedule to support a high-quality, investment-grade study, while continuing to make steady and deliberate progress toward development. The BFS is expected to be completed in 2027. A more detailed schedule and budget for the BFS are expected to be released in the coming months following full-scope alignment with other contractors selected to work on discreet portions of the overall project scope (“Specialist Contractors”).

Fluor is a global leader in engineering, mining, processing, and large-scale infrastructure delivery. The company portfolio includes extensive experience executing complex, large-scale gold and copper projects across North America and internationally in challenging environments including cold-weather and remote locations.

The bidding process for the Donlin Gold BFS was thorough and competitive, with participation from top-tier engineering firms. Fluor will integrate the other major work packages into the overall project and coordinate with other Specialist Contractors on key pieces of infrastructure and process unit operations. These include the power plant, the natural gas pipeline, and the pressure oxidation circuit and oxygen plant. Fluor will also bring substantial technical, engineering, and execution capabilities, supporting the design of what is anticipated to become the largest single operating gold mine in the United States. The BFS work will be primarily conducted at Fluor’s offices in Canada, utilize high value centers (HVC), with coordination from the Donlin Gold office and project site in Alaska.

“Fluor is pleased to be appointed as Donlin Gold’s partner to lead the BFS,” said Harish Jammula, Fluor’s President, Mining & Metals Business. “Our focus is on delivering an integrated, high-quality study, with an emphasis on safety, sustainability, quality, cost accuracy, constructability, and execution readiness as the project advances.”

“The selection of Fluor marks an important step in advancing the Donlin Gold project,” said Greg Lang, NOVAGOLD’s President and CEO. “They bring a proven track record of delivering complex projects on schedule and within budget, which is critical at this stage as we position Donlin Gold for development,” added John Paulson.

Scope of Work

Fluor has commenced work on the BFS and will be responsible for integrating workstreams from Specialist Contractors, advancing value and cost optimization, and delivering an integrated engineering, cost, and schedule framework.

Next Steps

Requests for proposals were issued in the fourth quarter of 2025 for Specialist Contractors to cover the power plant, pipeline, and pressure oxidation and oxygen plant scopes of work, which will be incorporated into the BFS.

In parallel, management has identified key project requirements and has begun recruiting critical roles to build the owner’s project team, while site activities continue to advance the next phase of development. This includes ongoing evaluation of geotechnical drilling as well as materials assessments along the planned upriver port and access road to support detailed design and the BFS.

The Company intends to advance these workstreams concurrently to support an integrated BFS and position the project for the next phase of development following completion of the study and project financing. The Company will continue to provide market updates as these activities progress.

About NOVAGOLD

NOVAGOLD is a well-financed precious metals company focused on the development of the Donlin Gold project in Alaska, one of the safest mining jurisdictions in the world. With approximately 40 million ounces of gold in the Measured and Indicated Mineral Resource categories (560 million tonnes at an average grade of approximately 2.22 grams per tonne, in the Measured and Indicated Mineral Resource categories on a 100% basis)1, inclusive of Proven and Probable Mineral Reserves, the Donlin Gold project is regarded to be one of the largest, highest-grade, and most prospective known open-pit gold deposits in the world. The Donlin Gold project is expected to produce an average of more than one million ounces per year over a 27-year mine life on a 100% basis once in production2.

About DGH

Donlin Gold Holdings (DGH), 100% wholly owned by Paulson Advisers LLC & its affiliates, is the 40% owner of the Donlin Gold project. DGH and NOVAGOLD together own 100% of Donlin Gold and share equal voting and operating control.

NOVAGOLD Contacts:

Mélanie Hennessey
Vice President, Corporate Communications

Frank Gagnon
Manager, Investor Relations

604-669-6227 or 1-866-669-6227
[email protected]
www.novagold.com

Cautionary Note Regarding Forward-Looking Statements

This media release includes certain “forward-looking information” and “forward-looking statements” (collectively “forward-looking statements”) within the meaning of applicable securities legislation, including the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “continue”, “ongoing”, “anticipates”, “believes”, “intends”, “estimates”, “potential”, “possible”, and similar expressions, or statements that events, conditions, or results “will”, “may”, “could”, “would” or “should” occur or be achieved. All statements, other than statements of historical fact, included herein are forward-looking statements. These forward-looking statements include statements regarding the anticipated timing of the release of the schedule and budget for the BFS and market updates relating to same; timing of the completion of the BFS; the preparation of the BFS; planned activities at the site relating to the preparation of the BFS; the mineral estimates at Donlin Gold and the anticipated production levels at Donlin Gold In addition, any statement that refers to expectations, intentions, projections or other characterizations of future events or circumstances are forward-looking statements. Forward-looking statements contained in this media release are based on a number of material assumptions, including but not limited to the following, which could prove to be significantly incorrect: our ability to achieve production at Donlin Gold; the cost estimates and assumptions contained in the 2025 Technical Report and the 2025 Technical Report Summary; estimated metal pricing, metallurgy, mineability, marketability and operating and capital costs, together with other assumptions underlying our resource and reserve estimates; our expected ability to develop adequate infrastructure and that the cost of doing so will be reasonable; assumptions that all necessary permits and governmental approvals will be obtained and the timing of such approvals; assumptions made in the interpretation of drill results, the geology, grade and continuity of our mineral deposits; our expectations regarding demand for equipment, skilled labor and services needed for exploration and development of mineral properties; operating or regulatory risks. Forward-looking statements are necessarily based on several opinions, estimates and assumptions that management of NOVAGOLD considered appropriate and reasonable as of the date such statements are made, are subject to known and unknown risks, uncertainties, assumptions, and other factors that may cause the actual results, activity, performance, or achievements to be materially different from those expressed or implied by such forward-looking statements. Forward-looking statements are not historical facts but instead represent the expectations of NOVAGOLD management’s estimates and projections regarding future events or circumstances on the date the statements are made. Important factors that could cause actual results to differ materially from expectations include the need to obtain additional permits and governmental approvals; the timing and likelihood of obtaining and maintaining permits necessary to construct and operate; availability of financing in the debt and capital markets; uncertainties involved in the interpretation of drill results and geological tests and the estimation of reserves and resources; changes in mineral production performance, exploitation and exploration successes; changes in national and local government legislation, taxation, controls or regulations and/or changes in the administration of laws, policies and practices, expropriation or nationalization of property and political or economic developments in the United States or Canada; the need for continued cooperation between the owners of Donlin Gold LLC, with government agencies and Native groups; risks of construction and mining projects such as accidents, equipment breakdowns, bad weather, disease pandemics, non-compliance with environmental and permit requirements, unanticipated variation in geological structures, ore grades or recovery rates; unexpected cost increases, which could include significant increases in estimated capital and operating costs; fluctuations in metal prices and currency exchange rates; whether or when a positive construction decision will be made regarding the Donlin Gold project; and other risks and uncertainties disclosed in NOVAGOLD’s most recent report on Forms 10-K, particularly the “Risk Factors” sections of those reports and other documents filed by NOVAGOLD with applicable securities regulatory authorities from time to time. Copies of these filings may be obtained by visiting NOVAGOLD’s website at www.novagold.com, or the SEC’s website at www.sec.gov, or on SEDAR+ at www.sedarplus.ca. The forward-looking statements contained herein reflect the beliefs, opinions and projections of NOVAGOLD on the date the statements are made. NOVAGOLD assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

1 Donlin Gold data as per the report titled “NI 43-101 Technical Report on the Donlin Gold project, Alaska, USA” with an effective date of November 30, 2025 (the “2025 Technical Report”) and the report titled “S-K 1300 Technical Report Summary on the Donlin Gold project, Alaska, USA” (the “2025 Technical Report Summary”), dated November 30, 2025. Donlin Gold possesses Measured Resources of approximately 9 Mt grading 2.67 g/t and Indicated Resources of approximately 551 Mt grading 2.21 g/t, each on a 100% basis and inclusive of Mineral Reserves, of which approximately 6 Mt of Measured Resources and approximately 330 Mt of Indicated Resources inclusive of Reserves is currently attributable to NOVAGOLD through its 60% ownership interest in Donlin Gold LLC. Exclusive of Mineral Reserves, Donlin Gold possesses Measured Resources of approximately 1.4 Mt grading 1.18 g/t and Indicated Resources of approximately 175 Mt grading 1.32 g/t, of which approximately 0.9 Mt of Measured Resources and approximately 105 Mt of Indicated Resources exclusive of Mineral Reserves is currently attributable to NOVAGOLD. Donlin Gold possesses Proven Reserves of approximately 9 Mt grading 2.29 g/t and Probable Reserves of approximately 495 Mt grading 2.02 g/t, each on a 100% basis, of which approximately 6 Mt of Proven Reserves and approximately 297 Mt of Probable Reserves is attributable to NOVAGOLD. Mineral Reserve and Resources have been estimated in accordance with NI 43-101 and S-K 1300.
2 Anticipated average annual gold production during full life of mine if put into production as contemplated in the 2025 Technical Report and the 2025 Technical Report Summary.

BRISBANE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on February 3, 2026 to 14 new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the “Committee”) without stockholder approval.

Four employees received stock options to purchase an aggregate of 58,000 shares of Pacira common stock and 14 employees received restricted stock units for an aggregate of 41,300 shares of Pacira common stock. The stock options have a 10-year term and a four-year vesting schedule with 25 percent of the underlying shares vesting on the first anniversary of the recipient’s first day of employment and in successive equal quarterly installments over the 36 months thereafter. The stock options have an exercise price of $21.02 per share, the closing trading price of Pacira common stock on the Nasdaq Global Select Market on the date of grant. Each restricted stock unit represents the contingent right to receive one share of Pacira common stock and the restricted stock unit awards vest annually in four equal installments beginning on February 1, 2027.

Vesting of the equity awards is subject to the employee’s continued employment with Pacira. Each equity award is also subject to the terms and conditions of an award agreement.

About Pacira

Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera®º, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing a pipeline of clinical-stage assets for musculoskeletal pain and adjacencies, its most advanced product candidate, PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy, is in Phase 2 clinical development for osteoarthritis of the knee. To learn more about Pacira, visit www.pacira.com.

, /PRNewswire/ -- Sabre Corporation (NASDAQ: SABR), a leading global travel technology company, today announced the renewal of its SabreSonic Passenger Service System (PSS) agreement with major Canadian carrier WestJet Airlines. The long-term commitment highlights WestJet's confidence in Sabre's airline technology as they continue their global expansion.

Through this multi-year renewal, WestJet will continue to deploy Sabre's reliable, scalable PSS capabilities, supporting operational excellence while laying the groundwork for future retailing modernization. The extended partnership positions WestJet to seamlessly assess Sabre's next-generation Offer and Order technologies as its business model advances, helping to ensure the airline is at the forefront of future retailing evolution.

"We're delighted to extend our collaboration with Sabre, our trusted technology partner for more than 25 years," said Tanya Foster, WestJet's Group EVP, Chief Information Officer. "With this latest agreement, we're thinking about the needs of our business and our customers both today and tomorrow. Sabre's proven technology, strong support, and forward-looking strategy make them the right partner to enable our strategic initiatives to unlock our growth aspirations for the future."

WestJet, which flies to more than 100 destinations across North & South America, Europe, and Asia, will continue to deploy the SabreSonic PSS, which powers streamlined airline reservations, ticketing, check-in and ancillary services. It also distributes its content through SabreMosaic™ Travel Marketplace and is well positioned for future technology adoption through the cloud-native, modular SabreMosaic Airline Retailing platform.

"As WestJet advances its expansion and growth plans, the airline will require increasingly sophisticated retailing capabilities," said Darren Rickey, SVP of Airline IT Sales and Services at Sabre. "This multi-year renewal reflects a strong vote of confidence in Sabre's vision for the future of airline retailing. As the industry shifts toward Offer and Order-based models, WestJet's continued partnership with Sabre signals a shared commitment to that transformation and a belief in the journey ahead."

SABR-F

About Sabre Corporation  
Sabre Corporation is a leading technology company that takes on the biggest opportunities and solves the most complex challenges in travel. Sabre harnesses speed, scale and insights to build tomorrow's technology today – empowering airlines, hoteliers, agencies and other partners to retail, distribute and fulfill travel worldwide. Headquartered in Southlake, Texas, USA, with employees across the world, Sabre serves customers in more than 160 countries globally. For more information visit www.sabre.com.

About WestJet
WestJet took to the skies in 1996 with just over 200 employees and three aircraft operating services to five destinations. Since then, WestJet has pioneered low-cost travel in Canada, cutting airfares in half, and increasing the flying population in Canada by more than 50 per cent. Following the 2025 integration of Sunwing, WestJet now has more than 14,000 WestJetters to support nearly 200 aircraft and connect guests to more than 100 destinations across North America, Central America, the Caribbean, Europe and Asia.

As a major Canadian employer that includes WestJet Airlines, WestJet Vacations, Vacances WestJet Quebec and Sunwing Vacations, the WestJet Group is Canada's leading low-cost airline and largest vacation provider, with a united purpose of providing affordable and accessible air and vacation travel to Canadians.

Learn more about WestJet at westjet.com/en-ca/who-we-are (also available in French)

Follow WestJet on Facebook at facebook.com/westjet
Follow WestJet on LinkedIn at linkedin.com/company/westjet
Follow WestJet on X at x.com/westjet and x.com/WestJetNews
Follow WestJet on Instagram at instagram.com/westjet/
Subscribe to WestJet on YouTube at youtube.com/westjet

Media: Liz Hands
[email protected]

Cassidy Smith-Broyles
[email protected]

[email protected]

[email protected]

Investors
Jim Mathias
[email protected]
[email protected] 

SOURCE Sabre Corporation

, /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that the U.S. Food and Drug Administration (FDA) has granted full approval of its Investigational Device Exemption (IDE) for the Next-Generation OCS ENHANCE Heart trial. This follows full FDA approval of the company's Next-Generation OCS DENOVO Lung IDE trial in January 2026 and conditional IDE approval for the ENHANCE Heart trial in August 2025.

The ENHANCE trial is a two-part clinical trial. Part A is designed to support prolonged heart perfusion using OCS™ Heart System. Part B is intended to demonstrate the superiority of OCS Heart perfusion in donation after brain death (DBD) cases when compared to DBD cases using static cold storage methods. Part B is intended to support the potential expansion of OCS Heart clinical indications to include standard criteria DBD hearts that are currently transplanted within 4 hours of preservation. The trial's total sample size, across both Part A and Part B, is expected to exceed 650 patients. TransMedics believes this would constitute the largest heart preservation for transplant trial ever, worldwide. Details of the OCS ENHANCE Heart trial are available on clinicaltrials.gov.

"Now that we have full and unconditional IDE approvals for both OCS ENHANCE Heart and DENOVO Lung trials, we are focused on trial execution and patient enrollment," said Waleed Hassanein, MD, President and Chief Executive Officer. "The OCS ENHANCE Trial is the first of its kind to build the highest level of clinical evidence to hopefully demonstrate that the Gen 2 OCS Heart platform is more than a preservation technology, and can be used to enhance and improve cardiac function and metabolic conditions on the OCS System. Importantly, it will provide what we believe to be the first randomized, controlled, and blinded clinical trial in donor heart preservation to hopefully prove the superiority of the OCS Heart perfusion to cold static storage for heart transplantation. Outcomes of ENHANCE and DENOVO trials should serve as major catalysts for heart and lung adoption in 2026 and beyond."

About TransMedics Group, Inc. 
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

Forward-Looking Statements 
This press release contains forward-looking statements. These forward-looking statements address various matters, including, among other things, future results and events, including the potential safety, efficacy, regulatory review or approval and commercial success of our products and product candidates and those relating to the Company's product development, pre-clinical testing, clinical studies, clinical and regulatory milestones and timelines, potential demonstration of the Gen 2 OCS Heart platform to enhance and improve cardiac function and metabolic conditions on OCS System, potential superiority of the OCS Heart perfusion to cold static storage for heart transplantation, potential outcomes of clinical trials, commercial opportunity and timelines, business strategies, potential growth opportunities and other statements that are predictive in nature. For this purpose, all statements other than statements of historical facts are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "hope," "could," "target," "predict," "seek" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties. Our management cannot predict all risks, nor can we assess the impact of all factors or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in or implied by any forward-looking statements we may make. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated in or implied by the forward-looking statements. Some of the key factors that could cause actual results to differ include: the fluctuation of our financial results from quarter to quarter; our ability to attract, train, and retain key personnel; our existing and any future indebtedness, including our ability to comply with affirmative and negative covenants under our credit agreements to which we will remain subject until maturity; our ability to sustain profitability; our need to raise additional funding and our ability to obtain it on favorable terms, or at all; our ability to use net operating losses and research and development credit carryforwards; that we have identified a material weakness in our internal control over financial reporting, and that we may identify additional material weaknesses in the future; our dependence on the success of the Organ Care System ("OCS"); our ability to expand access to the OCS through our National OCS Program ("NOP™"); our ability to improve the OCS platform, including by developing the next generation of the OCS products or expanding into new indications; our ability to scale our manufacturing and sterilization capabilities to meet increasing demand for our products; the rate and degree of market acceptance of the OCS; our ability to educate patients, surgeons, transplant centers and private and public payors of benefits offered by the OCS; our dependence on a limited number of customers for a significant portion of our revenue; our ability to maintain regulatory approvals or clearances for our OCS products in the United States, the European Union, and other select jurisdictions worldwide; our ability to adequately respond to Food and Drug Administration ("FDA"), or other competent authorities, follow-up inquiries in a timely manner; the impact of healthcare policy changes, including recently enacted or potential future legislation reforming the U.S. healthcare system, Organ Procurement and Transplantation Network ("OPTN"), or the FDA; the performance of our third-party suppliers and manufacturers; our use of third parties to transport donor organs and medical personnel for our NOP and our ability to maintain and grow our logistics capabilities to support our NOP to reduce dependence on third party transportation, including by means of attracting, training and retaining pilots, and the acquisition, maintenance or replacement of fixed-wing aircraft for our aviation transportation services or other acquisitions, joint ventures or strategic investments; our ability to maintain Federal Aviation Administration ("FAA") or other regulatory licenses or approvals for our aircraft transportation services; price increases of the components of our products and maintenance, parts and fuel for our aircraft; the timing or results of post-approval studies and any clinical trials for the OCS; our manufacturing, sales, marketing and clinical support capabilities and strategy; attacks against our information technology infrastructure; the economic, political and other risks associated with our foreign operations; our ability to protect, defend, maintain and enforce our intellectual property rights relating to the OCS and avoid allegations that our products or services infringe, misappropriate or otherwise violate the intellectual property rights of third parties; the pricing of the OCS, as well as the reimbursement coverage for the OCS in the United States and internationally; regulatory developments in the United States, European Union and other jurisdictions; the impact of any future U.S. government shutdowns; the extent and success of competing products or procedures that are or may become available; our ability to service our 1.50% convertible senior notes, due 2028; the impact of any product recalls or improper use of our products; our estimates regarding revenues, expenses and needs for additional financing; and other factors that may be described in our filings with the Securities and Exchange Commission (the "SEC"). Additional information will be made available in our annual and quarterly reports and other filings that we make with the SEC. The forward-looking statements in this press release speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and we are not able to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.

Investor Contact:
Brian Johnston
Laine Morgan
332-895-3222
[email protected] 

SOURCE TransMedics Group, Inc.

Vancouver, British Columbia – TheNewswire - February 9, 2026 - Rockland Resources Ltd. (the “Company” or "Rockland") (CSE: RKL) (OTCQB: BERLF) (FSE: GB2) is pleased to welcome Mr. Ewan Downie as Technical Advisor to the Rockland team.

Ewan has been intimately involved in exploration and development in the Red Lake Mining District for more than 20 years. During this period, he has participated in the discovery of multiple new gold deposits in the camp and, while at Premier Gold Mines Ltd where he held the position of President and CEO, was a part of the “Red Lake Tram” that was constructed to link the Red Lake Mining Complex with the Cochenour Mine Complex. Premier remained actively involved in several Red Lake projects at the time the Company was acquired by Equinox Gold in 2021.

“I have long been a fan of the Red Lake camp for its history of yielding high-grade, world-class, gold discoveries”, stated Ewan Downie. “The Cole Gold Mines Property has always been of interest, especially given that no modern exploration had been performed on this prospective property since 1973 - more than 50 years prior to being acquired by Rockland. The success of Great Bear, identifying a major gold deposit in a new geological environment away from the main “Mine Trend”, highlights the need to revisit properties like Cole in the pursuit of major new discoveries. I am excited to work with the Rockland Team to test new targets and assess the true potential at the historic Cole Gold Mine deposit”.

Mr. Mike England, CEO of Rockland stated: "We are honored to welcome Mr. Ewan Downie to Rockland’s Technical Advisory Board. His depth of geological experience and successes in the Red Lake Mining District will be invaluable as we now advance our historic Cole Gold Mines Project.”

The Company further announces it has arranged a non-brokered private placement of up to 1.25 million units ("Units") at a price of $0.20 per Unit for aggregate gross proceeds of $250,000.00 (the "Offering"). Each Unit will be comprised of one common share ("Share") and one transferable Share purchase warrant of the Company ("Warrant"). Each Warrant will entitle the Subscriber to purchase one Warrant Share for a 24-month period after the Closing Date at an exercise price of $0.275 per share. Net proceeds of the Financing will be used to advance the Corporation's Cole Gold Mines Project in Red Lake, Ontario and for general working capital purposes.

The Company further announces it has arranged a non-brokered private placement of up to 1,000,000 flow-through shares at a price of $0.25 per FT Share (the "FT Offering"), for aggregate gross proceeds of up to $250,000.

The FT shares will entitle the holder to receive the tax benefits applicable to flow-through shares, in accordance with provisions of the Income Tax Act (Canada). The proceeds from the sale of the FT Units will be used to advance the Company's Cole Gold Mines Project in Red Lake.

Each flow-through unit shall be comprised of one common share of the company issued on a flow-through basis and one-half of one common share purchase warrant to be issued on a non-flow-through basis. Each whole warrant shall entitle the holder thereof to acquire one common share of RKL at a price of $0.35 for a period of 24 months following the closing of the offering. The flow-through shares will qualify as flow-through shares (within the meaning of Subsection 66(15) of the Income Tax Act (Canada) and Section 359.1 of the Taxation Act (Quebec).

Finders' fees will be payable. Closing of the offering is subject to approval of the CSE. The securities issued under the offering, and any Shares that may be issuable on exercise of any such securities, will be subject to a statutory hold period expiring four months and one day from the date of issuance of such securities.

About Rockland Resources Ltd.

Rockland Resources is committed to unlocking value through focused mineral exploration and discovery. The company's flagship project is the historic Cole Gold Mines project in the prolific Red Lake district of Ontario. By leveraging geological expertise, disciplined exploration and strategic project development, Rockland Resources aims to deliver meaningful growth and long-term value to its shareholders.

We seek Safe Harbor.

On Behalf of the Board of Directors

Michael England, CEO & Director

For further information, please contact:

Mike England

Email: [email protected]

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

FORWARD-LOOKING STATEMENTS: This news release contains forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Investors are cautioned that these forward-looking statements are neither promises nor guarantees and are subject to risks and uncertainties that may cause future results to differ materially from those expected. These forward -looking statements are made as of the date hereof and, except as required under applicable securities legislation, the Company does not assume any obligation to update or revise them to reflect new events or circumstances. All of the forward-looking statements made in this press release are qualified by these cautionary statements and by those made in our filings with SEDAR in Canada (available at WWW.SEDAR.COM).

Analyst’s Disclosure: I/we have a beneficial long position in the shares of YMAX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1. KEY INFORMATION

Name of person dealing (Note 1)State Street Global Advisors & AffiliatesCompany dealt inAvadel Pharmaceuticals plcClass of relevant security to which
the dealings being disclosed relate (Note 2)$0.01 ordinary shares

Date of dealing06th February 2026 2. INTERESTS AND SHORT POSITIONS
(110)   Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

 LongShort Number(%)Number(%)(1) Relevant securities2,362,1862.42516%  (2) Derivatives (other than options)N/AN/A  (3) Options and agreements to
purchase/sellN/AN/A  Total2,362,1862.42516%          (b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)        

Class of relevant security:LongShort Number(%)Number(%)(1) Relevant securitiesN/A   (2) Derivatives (other than options)N/A   (3) Options and agreements to purchase/sellN/A   TotalN/A    3. DEALINGS (Note 4)
(110)   Purchases and sales

Purchase/saleNumber of relevant securitiesPrice per unit (Note 5)Purchase89621.69Sale1,80021.69         
(b) Derivatives transactions (other than options transactions)

Product name,
e.g. CFDNature of transaction(Note 6)

Number of relevant securities(Note 7)

Price per unit(Note 5)

N/A            
(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

Product name,
e.g. call optionWriting, selling,
purchasing
varying etc.Number of
securities to which
the option relates
(Note 7)Exercise
priceType, e.g.
American,
European etc.Expiry
dateOption money
paid/received
per unit (Note 5)N/A       (ii) Exercising

Product name,
e.g. call optionNumber of securitiesExercise price per
unit (Note 5)N/A   (d) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction
(Note 8)DetailsPrice per unit
(if applicable) (Note 5)N/A   4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.N/A Is a Supplemental Form 8 attached? (Note 9)
NO
Date of disclosure

09th February 2026
Contact name
Divya K

        
Telephone number                                

+918067452364
If a connected EFM, name of offeree/offeror with which connected
N/A
If a connected EFM, state nature of connection (Note 10)
N/A

Introduces continuous and on-demand, perpetual driver and rider verification to establish a new global safety and compliance standard for mobility platforms February 09, 2026 08:02 ET  | Source: HUB Cyber Security Ltd

LOS ANGELES and TEL AVIV, Israel, Feb. 09, 2026 (GLOBE NEWSWIRE) -- HUB Cyber Security Ltd. (Nasdaq: HUBC) (“HUB” or the “Company”), a global leader in secured data fabric and perpetual verification infrastructure, today announced the commercial launch of SecureRide™, its purpose-built trust infrastructure for the Transportation Network Companies (TNCs), in partnership with Fare Co-op, the driver-owned, city-managed rideshare platform.

SecureRide™ debuts as part of Fare Co-op Platform 2.0, introducing always-on, real-time verification of both drivers and riders, fundamentally replacing the static, point-in-time safety checks that dominate today’s rideshare industry.

The TNC market generated more than $260 billion in revenue in 2025 and is projected to exceed $400 billion by 2030, driven by urbanization, gig-based labor models, and the expansion of smart-city and autonomous transportation systems. Despite this scale, safety and compliance frameworks across the industry remain episodic and reactive, a structural failure as transaction volumes accelerate.

SecureRide™: Trust Infrastructure for Mobility

SecureRide™ applies HUB’s Secured Data Fabric (SDF) and perpetual verification architecture to the mobility ecosystem transforming trust from a periodic compliance requirement into real-time, foundational infrastructure.

Unlike traditional rideshare models that depend on annual or episodic background checks, SecureRide™ introduces Perpetual Know Your Driver (KYD) and Perpetual Know Your Customer (KYC), continuously validating both participants throughout the lifecycle of every ride.

According to publicly available reporting, a rideshare-related sexual harassment complaint is submitted every eight minutes in the United States alone, underscoring the limitations of snapshot-based safety frameworks. SecureRide™ is designed to close this gap by detecting and mitigating risk before incidents occur, rather than responding after the fact.

Hub’s Real-Time Verification Capabilities

SecureRide™ integrates multiple live, on-demand, data sources and enforcement layers, including criminal & sex offender registries, global watchlist, adverse media, motor vehicle records and other related source to establish a continuously verified trust perimeter around every ride.

Fare Co-Op’s Platform 2.0: Experience Designed for Scale

Alongside SecureRide™, Fare Co-op’s Platform 2.0 launching this month introduces a redesigned user experience tailored to a decentralized, driver-led network. New features include:

Ride Bidding & Dynamic Pricing: Increased flexibility for longer trips.Advanced Preferences: Options such as preferred driver gender selection and favorite driver lists.Embedded Social Connectivity: Deep-link referral systems and in-app money and credit transfers.
Strategic Impact

By embedding perpetual verification directly into ride-by-ride operations, SecureRide™ is designed to reduce insurance friction, lower claims exposure, and improve unit economics enabling a premium safety standard at mass-market accessibility.

More broadly, SecureRide™ demonstrates how perpetual verification infrastructure can operate at real-world transaction volumes across one of the world’s largest consumer-facing markets. As mobility expands into logistics, delivery, autonomous fleets, and municipal transportation, SecureRide™ positions HUB to play a foundational role in the future of global mobility infrastructure.

“Fare Co-op was founded on the belief that drivers and communities deserve a fairer and more accountable model,” said Ahmed Attia, Chairman & Co-Founder of Fare Co-op. “With SecureRide™, we are extending that philosophy to physical safety. Real-time accountability should be the baseline, not the exception, for anyone entering a vehicle.”

Noah Hershcoviz, CEO of HUB Cyber Security, commented: “SecureRide™ proves that perpetual verification can operate at live platform scale. This is the same trust architecture we deploy for banks and governments, which we will now be applying to one of the world’s most safety-critical consumer environments.”

About Fare Co-op

Fare Co-op is a multi-stakeholder, federated cooperative and a leading rideshare provider in the United States. The platform operates on a decentralized model led by local driver governance, emphasizing fair labor practices, community-centered safety, and sustainable transportation.

About HUB Cyber Security Ltd.

HUB Cyber Security Ltd. (Nasdaq: HUBC) is a global leader in confidential computing, AI-driven data fabric, and cybersecurity. HUB's Secured Data Fabric (SDF) empowers organizations to virtualize, secure, and analyze sensitive data across borders and silos generating real-time intelligence while meeting the highest regulatory standards. With operations across North America, Europe, and Israel, HUB partners with Fortune 100 companies, global banks, and sovereign institutions to secure the next generation of digital infrastructure.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are typically identified by words such as “plan,” “believe,” “expect,” “anticipate,” “intend,” “outlook,” “estimate,” “future,” “forecast,” “project,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict,” “seem,” “should,” “will,” “would” and other similar words and expressions, but the absence of these words does not mean that a statement is not forward-looking.

The forward-looking statements are based on the current expectations of the management of HUB, as applicable, and are inherently subject to uncertainties and changes in circumstances and their potential effects and speak only as of the date of such statement. There can be no assurance that future developments will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties, or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those discussed and identified in public filings made with the SEC by HUB and the following: (i) the Company’s ability to meet stock exchange continued listing standards and remain listed on the Nasdaq; (ii) significant uncertainty regarding the adequacy of HUB’s liquidity and capital resources and its ability to repay its obligations as they become due; (iii) the war between Israel and Hamas commenced in October 2023, which may harm Israel’s economy and HUB’s business; (iv) expectations regarding HUB’s strategies and future financial performance, including its future business plans or objectives, prospective performance and opportunities and competitors, revenues, products and services, pricing, operating expenses, market trends, liquidity, cash flows and uses of cash, capital expenditures, and HUB’s ability to invest in growth initiatives and pursue acquisition opportunities; (v) the outcome of any legal or regulatory proceedings against HUB in connection with our previously announced internal investigation or otherwise; (vi) competition, the ability of HUB to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (vii) limited liquidity and trading of HUB’s securities; (viii) geopolitical risk, including military action and related sanctions, and changes in applicable laws or regulations; (ix) the possibility that HUB may be adversely affected by other economic, business, and/or competitive factors; and (x) other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in HUB’s Annual Report on Form 20-F filed on May 1, 2025.

Should one or more of these risks or uncertainties materialize or should any of the assumptions made by the management of HUB prove incorrect, actual results may vary in material respects from those expressed or implied in these forward-looking statements.

All subsequent written and oral forward-looking statements concerning HUB or other matters addressed in this press release and attributable to HUB or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in the press release. Except to the extent required by applicable law or regulation, HUB undertakes no obligation to update these forward-looking statements to reflect events or circumstances after the date of this press release to reflect the occurrence of unanticipated events.

Investor Relations

Lytham Partners
Ben Shamsian
646-829-9701
[email protected]

DENVER, Feb. 09, 2026 (GLOBE NEWSWIRE) --

Dear Shareholders,

January marked my first full month as Chief Executive Officer of American Rare Earths, and I want to begin by thanking you for the trust you have placed in our team and in me personally. It has been an exceptionally busy and energizing start, and I am more convinced than ever that this company is uniquely positioned to become a cornerstone of the United States rare earths supply chain.

After some three decades in mining, I have learned that you can optimize many things in a project; costs, sequencing, processing choices; but you cannot change where the orebody is located. At American Rare Earths Halleck Creek, we have what I believe is a genuinely world-class combination: a very large, long-life rare earth deposit located in Wyoming, one of the world’s most attractive and mature mining jurisdictions with excellent infrastructure. In the Fraser Institute’s July 2025 survey, Wyoming ranked number four globally for overall investment attractiveness, underscoring the strength of the jurisdiction in which we are located.

Halleck Creek is the cornerstone asset of American Rare Earths and the foundation on which we intend to build a secure domestic supply of rare earths for the U.S. market. The work completed by the Company to prove out our processing flowsheet over the past year has been excellent, and the December 2025 announcement1 was a pivotal milestone. Using the updated preliminary Pre‑Feasibility Study mineral processing flowsheet, rare earth oxides were produced from Halleck Creek ore, and both a mixed rare earth oxalate and a mixed rare earth oxide were successfully created from purified leachate solution derived from impurity removal testwork. This is exactly the type of technical work that moves a project from promise toward production.

Looking ahead, our focus is clear. We are targeting completion of the Halleck Creek Pre‑Feasibility Study during 2026. In parallel, baseline studies and preparations to submit our mining permit in 2026 are moving forward, reflecting the advantage of operating in Wyoming’s well‑run and predictable natural resource permitting system. We are also analyzing the most cost and time‑efficient pathways to operate our process at larger scale so we can produce meaningful volumes of product to support discussions with potential offtake partners and strategic buyers. You will hear more about this as we accelerate through 2026.

Our strategy is unfolding against a backdrop of increasing U.S. policy support for domestic critical minerals. In March 2025, President Trump signed an executive order explicitly framing minerals; including rare earth elements; as a national security imperative and directing agencies to expedite permitting, deploy Defense Production Act tools, and mobilize financing to strengthen domestic mineral production. A subsequent directive launched a Section 232 investigation into imports of processed critical minerals and rare earth derivatives, signaling an intent to reduce reliance on foreign supply chains and support a resilient domestic manufacturing base. For a large-scale U.S. rare earth project in Wyoming, this policy environment is highly supportive and reinforces our conviction that American Rare Earths Halleck Creek can play a meaningful role in delivering on these national objectives.

We intend to be active participants in that policy landscape, not passive beneficiaries. The U.S. government has made clear that securing critical minerals is a domestic imperative, and programs are being put in place to streamline permitting and direct capital toward qualifying projects. My commitment is that we will pursue these opportunities thoughtfully and selectively, with a focus on funding and partnerships that strengthen our balance sheet and project without compromising discipline. In parallel, we will continue to deepen our engagement with stakeholders in Wyoming and at the federal level to ensure Halleck Creek is recognized as a strategic, long‑life, and sustainable source of domestic rare earths for the United States.

Capital markets alignment will also be a priority this year. American Rare Earths is, at its core, a U.S. story: U.S. assets, U.S. strategy, and a clear U.S. supply‑chain role. I am carefully reviewing options and opportunities for a potential U.S. listing, in addition to our existing ASX and OTCQX presence, to better reflect our asset base and broaden our investor reach into the world’s largest equity market. Any decision will be grounded in what best enhances long‑term value for existing shareholders while positioning us to fund development efficiently.

While Halleck Creek is our flagship, we are also mindful of the broader portfolio. We continue to assess La Paz in Arizona, Searchlight in Nevada, and Beaver Creek in Wyoming as part of a coherent U.S. growth pipeline that complements our cornerstone project. The bar for capital allocation will remain high: we will prioritize investments that enhance scale, optionality, and returns, while preserving the financial flexibility needed to take Halleck Creek through study, larger scale demonstration, permitting, and ultimately into construction.

On a more personal note, I want to share how it feels to step into this role at this moment. American Rare Earths is at a genuinely transformative point in its journey. In my first weeks on the ground, I have been struck by the quality of our people; from the technical teams driving metallurgy and resource work, to the permitting and community specialists building trust in Wyoming, to the finance and corporate teams who have kept the company moving forward through the CEO transition. They have delivered key milestones and put us on solid footing; my job is to harness that momentum, bring additional operating and financing experience to the table, and help organize the many moving pieces involved in developing a mine of this scale.

Mining is a long‑cycle business, and I know you are entrusting us not just with capital, but with time and patience. There will be challenges along the way; markets will move, policy will evolve, and some work will sometimes take longer than any of us would like. But we start from a position many projects would envy: a world‑class asset, in a world‑class jurisdiction, at a time when the Western world is waking up to the strategic importance of rare earths and the need for secure, resilient, transparent supply chains. Our task is to match that opportunity with the same level of discipline, humility, and determination that has underpinned the best mining projects I have seen over my career.

I am grateful for your continued support and engagement as shareholders. Over the coming months, you can expect communication from me and the team as we advance the Pre‑Feasibility Study, progress permitting, refine our demonstration and scale‑up plans, and continue to navigate the evolving U.S. policy and capital markets environment. I look forward to meeting many of you in person as we share the American Rare Earths story more widely across the United States and internationally.

Thank you for joining us on this journey.

Sincerely,
Mark Wall
Chief Executive Officer
This announcement has been authorized for release by the CEO of American Rare Earths Limited.

Investors can follow the Company’s progress at www.americanree.com

About American Rare Earths Limited:

American Rare Earths (ASX: ARR | OTCQX: ARRNF | ADR: AMRRY) is a critical minerals company at the forefront of reshaping the U.S. rare earths industry. Through its wholly owned subsidiary, Wyoming Rare (USA) Inc. (“WRI”), the company is advancing the Halleck Creek Project in Wyoming—a world-class rare earth deposit with the potential to secure America’s critical mineral independence for generations. Located on Wyoming State land, the Cowboy State Mine within Halleck Creek offers cost-efficient open-pit mining methods and benefits from streamlined permitting processes in this mining-friendly state.

With plans for onsite mineral processing and separation facilities, Halleck Creek is strategically positioned to reduce U.S. reliance on imports—predominantly from China—while meeting the growing demand for rare earth elements essential to defense, advanced technologies, and economic security. As exploration progresses, the project’s untapped potential on both State and Federal lands further reinforces its significance as a cornerstone of U.S. supply chain security. In addition to its resource potential, American Rare Earths is committed to environmentally responsible mining practices and continues to collaborate with U.S. Government-supported R&D programs to develop innovative extraction and processing technologies for rare earth elements.

For further information contact:

Media Contact:

Susan Assadi
[email protected]
347 977 7125

Investor Relations US Contact:

Beverly Jedynak
[email protected]
312 943 1123

_______________

1 ASX announcement: 16 December 2025

World Liberty Financial’s native token WLFI, backed by the Donald J. Trump family, has shown strong momentum despite weakness in the broader crypto market. In the last 24 hours, WLFI price has jumped nearly 10% and is trading around $0.109, pushing its market cap close to $2.91 billion. 

This has raised questions among traders, why is WLFI Price Up Today?

Whale Buying WLFI Token Triggers Price RallyOne of the biggest reasons behind the price rise is heavy buying activity from a large investor. Blockchain analytics platform Lookonchain reported that a new wallet was recently created and funded with 10 million USDC. 

Meanwhile, the wallet immediately used this capital to buy WLFI tokens.

So far, this investor has purchased around 47.6 million WLFI tokens at an average price of $0.109. The wallet still holds about 4.83 million USDC, which suggests more buying could happen soon.

WLFI Trading Volume Jumps 100%Another major factor driving the rally is a massive increase in trading activity. WLFI recorded more than $227 million in trading volume in just 24 hours. This is almost a 100% jump compared to previous days.

Even though WLFI is still down about 52% over the past year, this sudden spike shows that momentum is returning to the token.

Hype Around the Upcoming World Liberty Forum at Mar-a-LagoAnother key reason fueling the rally is growing excitement around the World Liberty Forum. World Liberty Financial has announced that it will host a major event on February 18, 2026, at Mar-a-Lago in Palm Beach.

The forum is expected to bring together influential leaders from finance, technology, and policy. Big names from organizations like Goldman Sachs, Franklin Templeton, the CFTC, and even FIFA are expected to attend.

However, any announcement from this event could push the WLFI token price up.

WLFI Price OutlookLooking at the daily chart, WLFI has been moving inside a broad horizontal range for several months. Price has repeatedly failed to break above the $0.18 price level, leading to multiple pullbacks.

Now the token has returned to what traders call a demand zone, an area where buyers previously stepped in with strong volume. This lower band around $0.08 has acted as a floor before, and price reaction here is often important.

If the base holds, a sharper recovery move could develop, possibly starting a new upward trend phase towards $0.24. If it fails, WLFI could slip into a lower range again.

Trust with CoinPedia:CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.

Why Trust CoinGape

CoinGape has covered the cryptocurrency industry since 2017, aiming to provide informative insights to our readers. Our journal analysts bring years of experience in market analysis and blockchain technology to ensure factual accuracy and balanced reporting. By following our Editorial Policy, our writers verify every source, fact-check each story, rely on reputable sources, and attribute quotes and media correctly. We also follow a rigorous Review Methodology when evaluating exchanges and tools. From emerging blockchain projects and coin launches to industry events and technical developments, we cover all facets of the digital asset space with unwavering commitment to timely, relevant information.

Bitcoin and XRP prices showed stability on Monday as China advised its banks to reduce exposure to US Treasuries. Bitcoin price hovered around $70,000, recovering from last week’s downturn driven by global financial concerns. 

Over the weekend, XRP moved steadily, around the $1.40 mark. Ethereum had also been robust as it stood over $2,000. The wider crypto market was cautiously optimistic, responding to tensions of the geopolitical environment.

China Urges Major Banks to Cut U.S. Treasury Holdings Chinese regulators have recently directed major domestic banks to begin reducing their exposure to U.S. Treasury bonds. The shift is motivated by issues of volatility and risks of excessive holding of U.S. government securities in the market. 

The financial institutions that have a lot of U.S. debt are being encouraged to reduce those positions in stages.

BREAKING: China has told domestic banks to stop adding and begin reducing exposure to U.S. Treasuries.

This removes a steady source of foreign demand for U.S. government debt. Lower external demand for Treasuries can push yields higher and increase U.S. borrowing costs over… pic.twitter.com/riloI93nd9

— Bull Theory (@BullTheoryio) February 9, 2026

This directive is said not to concern the official state holdings of China but has been directed to part of the biggest commercial banks of the country. It is claimed that the guidance was published prior to the phone call between the U.S. President Donald Trump and Chinese President Xi Jinping last week. In the same call, Trump affirmed that he will be coming to China in April.

The statistics indicate that direct ownership of U.S. Treasuries by China has dropped to 682 billion a 17 year low compared with a high of approximately 1.3 trillion. After the report, the 10-year Treasury yields increased marginally to 4.24 indicating that the markets reacted to the declining foreign backing.

Bitcoin Price Holds Near $70K as Accumulation Hits 2021 High Bitcoin price traded at $70,100 on Monday, with a 24-hour drop of 0.96%. The previous week recorded a significant downward trend of almost 10% and Bitcoin dropped to $60,000 on Friday but recovered over the weekend. On Sunday, it retested resistance at close of $73,072.

If the recovery holds, further gains could push the Future Bitcoin outlook toward the next resistance at $73,300. However, holding above the $69,000 support is crucial for consolidation. 

A failure would cause a retest of $65,000. Interestingly, accumulation addresses have registered their greatest inflows since 2021, which indicates increased purchases by smart money under this consolidation.

XRP Price Struggles to Hold $1.40 Amid Rising ETF Inflows XRP price slipped by 2% to $1.40 over the last 24 hours, signaling possible weakness in momentum. On Thursday, XRP broke below its lower trendline and dipped to a $1.11 low on Friday. The token has since hovered around the same level throughout the weekend after briefly retesting the broken trendline.

Source: Sosovalue data Should XRP price continue to be supported at a price point above $1.40, it may consolidate. A breakdown would, however, send the prices towards the support of $1.30. Nevertheless, XRP spot ETFs recorded net inflows of $39.04 million last week.

What’s Next For Bitcoin And XRP Price? Bitcoin and XRP prices are resistant to the emerging uncertainty in the world as China encourages banks to reduce U.S. Treasury holdings. The mood on the market remains optimistically reserved, but further price changes will likely depend on geopolitical processes and reactions of investors to the macroeconomic evolution.

Frequently Asked Questions (FAQs) Bitcoin and XRP prices are holding steady due to investor accumulation and optimism despite geopolitical tensions and macroeconomic policy changes.

China’s reduction in U.S. Treasury exposure signals distrust in U.S. debt, indirectly boosting interest in decentralized assets like Bitcoin.

Bitcoin price recovers to $71,000 following a volatile week. Institutional "buy the dip" activity offsets retail panic as BTC stabilizes post-flash crash.

Analysts at Bernstein said the current bitcoin downturn reflects a crisis of confidence rather than structural damage.

Miners are facing significant challenges, with bitcoin revenue per petahash falling by half from a peak of $70 to $35. Feb 9, 2026, 11:06 a.m.

Bitcoin’s BTC$70,411.45 mining difficulty dropped by around 11%, its largest decline since China’s 2021 crackdown on the industry, after a sharp decline in hashrate triggered by plunging prices and widespread winter storm-related outages in the U.S.

Mining difficulty, which determines how hard it is to find new Bitcoin blocks, adjusts roughly every two weeks to maintain a 10-minute block interval on the network.

STORY CONTINUES BELOW

The latest change brought the metric down from over 141.6 trillion to about 125.86 trillion, according to Blockchain.com data, signaling a steep drop in the number of active machines securing the network.

The decline follows a series of blows to miners. Bitcoin prices have fallen significantly from an all-time high of $126,000 in October to around $69,500.

That price drop forced many miners, especially those running outdated equipment and facing high energy costs, to shut down. Some also repurposed their hardware to focus on artificial intelligence (AI), as megacap firms offer stable contracts and often economically irresistible terms.

Bitfarms (BITF) notably saw its share price surge after saying it’s no longer a bitcoin company, and is instead focusing on data center development for high-performance computing and AI workloads.

Bitcoin mining revenue on a per terahash basis, measured via the hashprice, has plunged from nearly $70 at the time the cryptocurrency was trading at an all-time high, to now stand at little over $35.

Severe winter storms, particularly in Texas, compounded the situation. Grid operators issued curtailment requests to conserve electricity for residential users. Public mining firms scaled back production, with some seeing daily bitcoin output fall by more than 60%.

Although a drop in difficulty might appear alarming, it functions as a self-correcting mechanism. For miners who remain online, the reduced competition can increase profitability and help maintain the business model.

Historically, major difficulty drops have also signaled market capitulation, often preceding a stabilization or rebound in price as miners sell the BTC they mine to cover operational expenses.